[Glutamate antibodies in the development of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonian syndrome in C57B1/6 mice].
The experiments on mice C57B1/6 with MPTP-induced Parkinsonian syndrome have shown that preliminary and simultaneous intranasal injection of glutamate antibodies inhibit development of the syndrome. Administration of glutamate antibodies decreased tremor, rigidity and increased horizontal locomotion, movement velocity in the open field.
Davydova
T V
TV
Fomina
V G
VG
Gorbatov
V Iu
VIu
Vetrilé
L A
LA
Kucherianu
V G
VG
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000494:pharmacology*; D018698:Glutamic Acid / Q000276:immunology; D008124:Locomotion / Q000187:drug effects / Q000276:immunology; D020267:MPTP Poisoning / Q000188:drug therapy* / Q000276:immunology; D051379:Mice; D009498:Neurotoxins / Q000633:toxicity*; D013577:Syndrome; D014202:Tremor / Q000188:drug therapy / Q000276:immunology
D000906:Antibodies; D009498:Neurotoxins; D018698:Glutamic Acid; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine